| | | |

New Artificial Intelligence Tool Measures Mesothelioma Tumors

ByHolly Zink

New Artificial Intelligence Tool Measures Mesothelioma TumorsA new artificial intelligence tool can measure mesothelioma tumors without any human input.

Automated mesothelioma tumor measurement is now possible. The artificial intelligence algorithm performed well. There were 266 malignant pleural mesothelioma tumors analyzed.

This is the largest study of its kind performed in mesothelioma. And this is the first description of an automated artificial intelligence tool.

Inconsistent Mesothelioma Measurement During Clinical Assessment

In malignant pleural mesothelioma, complex tumors result in inconsistent clinical assessment. Promising new methods need practical computer automation methods.

A new publication showed an automated tool for this purpose. This study compared a new artificial intelligence tool with human standard clinical assessment.

This study looked at mesothelioma patients treated with chemotherapy.

Evaluating How Well the New Tool Works

This was a multi-center retrospective study. A total of 183 patients were split into groups. One group was for training and internal validation. A second group was used for external validation.

Humans annotated patient records to train the new artificial intelligence tool. Statistical analysis evaluated the artificial intelligence tool’s performance.

Scientists defined success between 20% to 30% change compared with human clinical assessment. The Kaplan-Meier method assessed patient survival.

Human and Artificial Intelligence Responses Mostly Agreed

Human and artificial intelligence assessments were very similar. Agreement between human clinical assessment and the new artificial intelligence tool was strong.

Human and artificial intelligence responses agreed in 67% of validation cases. Tool errors occurred in 4 out of 60 assessments.

Clinical Implications of a New Tool

The new artificial intelligence tool reported here is an important clinical development.

The tool needs more training and optimization. Then, it has the capacity of improving clinical decision-making. This tool will enable more practical tumor measurements.

This tool will show doctors the exact measurement of a mesothelioma tumor. This will impact treatment planning. It will allow doctors to make a more tailored treatment plan. It will also reduce the number of toxic treatments. This new tool will lower patient treatment costs.

This tool will cut the minimal measurable disease threshold. In other words, if we can measure the exact tumor size, there is no need to report broad categories.

Understanding Where to Go From Here

Scientists have released the first automated artificial intelligence tool for mesothelioma assessment.

Dr. Andrew Kidd at the Queen Elizabeth University Hospital states, “…these data represent a strong proof-of-principle for development of similar tools for other cancers.”

The tool’s performance may be further improved with more training and calibration.

Sources

Kidd AC, Anderson O, Cowell GW, et al. Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. Thorax Published Online First: 02 February 2022. doi: 10.1136/thoraxjnl-2021-217808 http://dx.doi.org/10.1136/thoraxjnl-2021-217808

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    ByAlex Strauss

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    ByAlex Strauss

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    ByAlex Strauss

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…